1 week Ago By ABMN Staff
Shares of ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC – Get Free Report ) have been assigned an average rating of “Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation.
The average twelve-month target price among brokers that have covered the stock in the last year is $18.00. Several research analysts recently issued reports on the company.
Stifel Nicolaus initiated coverage on ORIC Pharmaceuticals in a research note on Friday. They issued a “buy” rating and a $20.00 price objective on the stock.
Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and set a $21.
00 price target on shares of ORIC Pharmaceuticals in a research report on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Thursday, June 20th. Finally, Oppenheimer lowered their price target on ORIC Pharmaceuticals from $17.
00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. View Our Latest Analysis on ORIC Pharmaceuticals Hedge Funds Weigh In On ORIC Pharmaceuticals ORIC Pharmaceuticals Price Performance Shares of ORIC opened at $9.
65 on Monday. ORIC Pharmaceuticals has a 1 year low of $5.27 and a 1 year high of $16.
65. The stock has a market capitalization of $650.62 million, a price-to-earnings ratio of -5.
36 and a beta of 1.12. The business’s 50 day simple moving average is $9.
72 and its 200-day simple moving average is $10.15. ORIC Pharmaceuticals ( NASDAQ:ORIC – Get Free Report ) last released its earnings results on Monday, August 12th.
The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.
03). On average, sell-side analysts expect that ORIC Pharmaceuticals will post -1.78 earnings per share for the current year.
About ORIC Pharmaceuticals ( Get Free Report ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. Featured Stories Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
